A Phase I/II Study of Intralesional Recombinant Tumor Necrosis Factor in Patients With AIDS-Related Cutaneous Kaposi's Sarcoma

Inclusion Criteria

Patients must have:

* Biopsy-proven Kaposi's sarcoma (KS) with multiple cutaneous lesions.
* Minimum life expectancy of 3 months.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

* Clinically significant cardiac disease.
* Known hemorrhagic diathesis or active bleeding disorder.
* Clinically apparent vascular disease.
* Known lipoprotein disorders.
* History of seizure disorder or central nervous system (CNS) metastasis.
* Additional malignancy.

Concurrent Medication:

Excluded:

* Cardiac agents.
* Anticoagulants.
* Thrombolytic agents.
* Nonsteroidal anti-inflammatory drugs.
* Corticosteroids.
* Aspirin.
* Vasodilators.

Patients with the following are excluded:

* Additional malignancies or other conditions listed in Patient Exclusion Co-Existing Conditions.

Prior Treatment:

Excluded within 4 weeks of study entry:

* Chemotherapy.
* Radiotherapy.
* Immunotherapy.